Objective:To observe the heart function、MEE and serum FFA of Shenqiyixin prescription for heart qi(yang)deficiency with blood stasis and fluid retention type of chronic heart failure patients,to evaluate the clinical...Objective:To observe the heart function、MEE and serum FFA of Shenqiyixin prescription for heart qi(yang)deficiency with blood stasis and fluid retention type of chronic heart failure patients,to evaluate the clinical efficacy and safety.Methods:64 cases with chronic heart failure of heart qi(yang)deficiency with blood stasis and fluid retention were randomly divided into two groups,3 cases were excluded,31 cases in the control group and 30 cases in the treatment group.The control group was treated with western medicine,and the treatment group was treated with Shenqiyixin prescription additionally.The course of treatment was 3 weeks.Observe the changes of TCM syndrome score,6MWD,LVEF,cESS,MEE,serum NTproBNP,serum FFA and safety indexes of each group before and after treatment.Results:after treatment,the TCM Syndromes of each group were improved.The total effective rate of the treatment group was 93.33%,and the control group was 83.87%.The treatment group was more effective(P<0.05).After treatment,the TCM syndrome score,cESS,MEE,NTproBNP and FFA of each group were decreased,6MWD and LVEF were increased(P<0.05),and the treatment group was superior to the control group(P<0.05).Conclusion:Shenqiyixin prescription can improve the TCM syndrome and heart function in patients with chronic heart failure of heart qi(yang)deficiency with blood stasis and fluid retention,at the same time,it can reduce the level of MEE and serum FFA in patients with heart failure.展开更多
Objective To study the urinary excretion of aquaporin-2 (AQP2) water channel protein, and the relationship between urine AQP2 concentration and renal AQP2 gene expression in chronic heart failure (CHF) rats. Methods...Objective To study the urinary excretion of aquaporin-2 (AQP2) water channel protein, and the relationship between urine AQP2 concentration and renal AQP2 gene expression in chronic heart failure (CHF) rats. Methods Male Sprague-Dawley rats (200?g-250?g) underwent either a left coronary artery ligation, a model of CHF, or a sham-operation. Nine weeks after surgery, urinary AQP2 concentrations and renal AQP2 protein levels were measured by Western blot. Results The urinary concentration of AQP2 water channel protein increased significantly in CHF rats as compared with sham-operated rats (365.6%±102.9% vs 98.5%±47.6%, P<0.01). There was positive correlation between urinary AQP2 concentration and renal AQP2 protein expression (r=0.89, P<0.01). Conclusion The urinary concentration of AQP2 water channel protein increases significantly in chronic heart failure rats.展开更多
目的:探讨火龙罐辅助治疗心肺气虚、血瘀饮停慢性心力衰竭(chronic heart failure,CHF)患者的效果。方法:选择2022年2月—2023年8月厦门市中医院心血管科确诊的120例心肺气虚、血瘀饮停CHF患者作为研究对象,按照随机数表法将患者分为两...目的:探讨火龙罐辅助治疗心肺气虚、血瘀饮停慢性心力衰竭(chronic heart failure,CHF)患者的效果。方法:选择2022年2月—2023年8月厦门市中医院心血管科确诊的120例心肺气虚、血瘀饮停CHF患者作为研究对象,按照随机数表法将患者分为两组,每组60例。对照组接受常规西医治疗,观察组在此基础实施火龙罐辅助治疗,比较两组治疗前后心功能分级、中医症候积分、明尼苏达心力衰竭生活质量问卷(Minnesota living heart failure questionnaire,MLHFQ)评分、N末端B型脑钠尿肽前体(N terminal pro B type natriuretic peptide,NT-proBNP)水平、临床效果及随访6个月再住院情况。结果:观察组治疗后心功能分级低于对照组,差异有统计学意义(P<0.05);观察组治疗后中医症候积分、MLHFQ评分、NT-proBNP水平低于对照组,且观察组治疗前后中医症候积分、MLHFQ评分、NT-proBNP差值大于对照组,差异有统计学意义(P<0.05);观察组临床效果优于对照组,差异有统计学意义(P<0.05);两组随访6个月再住院率比较,差异无统计学意义(P>0.05)。结论:火龙罐辅助治疗有助于改善心肺气虚、血瘀饮停CHF患者心功能分级、中医症候积分,提升生活质量,降低NT-proBNP水平,提高临床效果。展开更多
基金Natural Science Foundation of Heilongjiang Province(No.LH2019H104).
文摘Objective:To observe the heart function、MEE and serum FFA of Shenqiyixin prescription for heart qi(yang)deficiency with blood stasis and fluid retention type of chronic heart failure patients,to evaluate the clinical efficacy and safety.Methods:64 cases with chronic heart failure of heart qi(yang)deficiency with blood stasis and fluid retention were randomly divided into two groups,3 cases were excluded,31 cases in the control group and 30 cases in the treatment group.The control group was treated with western medicine,and the treatment group was treated with Shenqiyixin prescription additionally.The course of treatment was 3 weeks.Observe the changes of TCM syndrome score,6MWD,LVEF,cESS,MEE,serum NTproBNP,serum FFA and safety indexes of each group before and after treatment.Results:after treatment,the TCM Syndromes of each group were improved.The total effective rate of the treatment group was 93.33%,and the control group was 83.87%.The treatment group was more effective(P<0.05).After treatment,the TCM syndrome score,cESS,MEE,NTproBNP and FFA of each group were decreased,6MWD and LVEF were increased(P<0.05),and the treatment group was superior to the control group(P<0.05).Conclusion:Shenqiyixin prescription can improve the TCM syndrome and heart function in patients with chronic heart failure of heart qi(yang)deficiency with blood stasis and fluid retention,at the same time,it can reduce the level of MEE and serum FFA in patients with heart failure.
基金ThisworkwassupportedbyagrantfromtheGuangdongNatural ScienceFoundation (No .970 35 5 )
文摘Objective To study the urinary excretion of aquaporin-2 (AQP2) water channel protein, and the relationship between urine AQP2 concentration and renal AQP2 gene expression in chronic heart failure (CHF) rats. Methods Male Sprague-Dawley rats (200?g-250?g) underwent either a left coronary artery ligation, a model of CHF, or a sham-operation. Nine weeks after surgery, urinary AQP2 concentrations and renal AQP2 protein levels were measured by Western blot. Results The urinary concentration of AQP2 water channel protein increased significantly in CHF rats as compared with sham-operated rats (365.6%±102.9% vs 98.5%±47.6%, P<0.01). There was positive correlation between urinary AQP2 concentration and renal AQP2 protein expression (r=0.89, P<0.01). Conclusion The urinary concentration of AQP2 water channel protein increases significantly in chronic heart failure rats.
文摘目的:探讨火龙罐辅助治疗心肺气虚、血瘀饮停慢性心力衰竭(chronic heart failure,CHF)患者的效果。方法:选择2022年2月—2023年8月厦门市中医院心血管科确诊的120例心肺气虚、血瘀饮停CHF患者作为研究对象,按照随机数表法将患者分为两组,每组60例。对照组接受常规西医治疗,观察组在此基础实施火龙罐辅助治疗,比较两组治疗前后心功能分级、中医症候积分、明尼苏达心力衰竭生活质量问卷(Minnesota living heart failure questionnaire,MLHFQ)评分、N末端B型脑钠尿肽前体(N terminal pro B type natriuretic peptide,NT-proBNP)水平、临床效果及随访6个月再住院情况。结果:观察组治疗后心功能分级低于对照组,差异有统计学意义(P<0.05);观察组治疗后中医症候积分、MLHFQ评分、NT-proBNP水平低于对照组,且观察组治疗前后中医症候积分、MLHFQ评分、NT-proBNP差值大于对照组,差异有统计学意义(P<0.05);观察组临床效果优于对照组,差异有统计学意义(P<0.05);两组随访6个月再住院率比较,差异无统计学意义(P>0.05)。结论:火龙罐辅助治疗有助于改善心肺气虚、血瘀饮停CHF患者心功能分级、中医症候积分,提升生活质量,降低NT-proBNP水平,提高临床效果。
